Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cell Design Labs

Kite Pharma once again looks to Amgen

William Go and Jeff Aycock fourth and fifth senior figures to join from Amgen this year

- PMLiVE

Hepatitis C therapies: dawn of a new age

New treatments from the likes of Merck & Co, Janssen and Gilead offer significant treatment advances

- PMLiVE

Gilead’s RSV drug clears mid-stage trial

Late-stage data demonstrates GS-5806 is effective in treating the infection

- PMLiVE

Oral hepatitis C regimens tackle advanced liver disease

 New data released at the International Liver Congress by AbbVie, Merck & Co and Gilead

- PMLiVE

WHO raises red flag on hepatitis C drug pricing

Warns about cost of Gilead’s Sovaldi and J&J’s Olysio

- PMLiVE

Gilead taken to task over Sovaldi pricing

US politicians question high cost of new hepatitis C drug

- PMLiVE

CURx buys rights to Gilead’s lung infection drug

Agrees deal for fosfomycin/tobramycin combination

- PMLiVE

Mylan to sell Gilead’s medicines in India

Includes HIV treatments Viread, Truvada and Stribild

- PMLiVE

Kite Pharma appoints head of regulatory affairs

Rizwana Sproule joins from Amgen

- PMLiVE

EU clears Gilead’s hepatitis C therapy Sovaldi

Region’s first all-oral treatment approved to treat the virus

- PMLiVE

FDA sets standard review for Gilead’s idelalisib in NHL

Comes despite accelerated review for drug’s use in chronic lymphocytic leukaemia

Kite Pharma names Cynthia Butitta as CFO

She helped broker Pfizer’s takeover of NextWave Pharmaceuticals

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links